OTCMKTS:PKPH - Peak Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0950 -0.01 (-9.52 %)
(As of 03/24/2019 04:00 PM ET)
Previous Close$0.0950
Today's Range$0.0911 - $0.1050
52-Week Range$0.0550 - $0.30
Volume30,712 shs
Average Volume36,759 shs
Market Capitalization$7.44 million
P/E RatioN/A
Dividend YieldN/A
Peak Pharmaceuticals, Inc. operates as a bio­pharmaceutical and nutraceutical company in the United States. The company focuses to develop, manufacture, market, and sell medicinal products based on extracts from hemp. It is involved in the development of over-the-counter, THC­free, hemp based products for human market for the prevention and alleviation of symptoms associated with inflammatory and auto-immune diseases. The company was formerly known as Cannabis Therapy Corporation and changed its name to Peak Pharmaceuticals, Inc. in December 2014. Peak Pharmaceuticals, Inc. was incorporated in 2007 and is based in Scottsdale, Arizona.

Receive PKPH News and Ratings via Email

Sign-up to receive the latest news and ratings for PKPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolOTCMKTS:PKPH



Sales & Book Value

Annual SalesN/A


Net Income$-50,000.00


Market Cap$7.44 million
Next Earnings DateN/A
OptionableNot Optionable

Peak Pharmaceuticals (OTCMKTS:PKPH) Frequently Asked Questions

What is Peak Pharmaceuticals' stock symbol?

Peak Pharmaceuticals trades on the OTCMKTS under the ticker symbol "PKPH."

Has Peak Pharmaceuticals been receiving favorable news coverage?

Media stories about PKPH stock have trended neutral on Sunday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Peak Pharmaceuticals earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the stock's share price in the immediate future.

Who are some of Peak Pharmaceuticals' key competitors?

What other stocks do shareholders of Peak Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Peak Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Aphria (APHQF), Canopy Growth (CGC), Alibaba Group (BABA), General Electric (GE), OrganiGram (OGRMF), CONSOL Coal Resources (CCR), QUALCOMM (QCOM) and Insys Therapeutics (INSY).

Who are Peak Pharmaceuticals' key executives?

Peak Pharmaceuticals' management team includes the folowing people:
  • Mr. Neil T. Reithinger, CEO, Pres, CFO, Principal Accounting Officer, Treasurer, Sec. & Director (Age 49)

How do I buy shares of Peak Pharmaceuticals?

Shares of PKPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Peak Pharmaceuticals' stock price today?

One share of PKPH stock can currently be purchased for approximately $0.0950.

How big of a company is Peak Pharmaceuticals?

Peak Pharmaceuticals has a market capitalization of $7.44 million. Peak Pharmaceuticals employs 1 workers across the globe.

What is Peak Pharmaceuticals' official website?

The official website for Peak Pharmaceuticals is http://www.peakpharma.com.

How can I contact Peak Pharmaceuticals?

Peak Pharmaceuticals' mailing address is 14201 N. HAYDEN ROAD SUITE A-1, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-659-6404 or via email at [email protected]

MarketBeat Community Rating for Peak Pharmaceuticals (OTCMKTS PKPH)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  54 (Vote Outperform)
Underperform Votes:  26 (Vote Underperform)
Total Votes:  80
MarketBeat's community ratings are surveys of what our community members think about Peak Pharmaceuticals and other stocks. Vote "Outperform" if you believe PKPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PKPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel